# Filtered and unfiltered lipoaspirates reveal novel molecular insights and therapeutic potential for osteoarthritis treatment: a preclinical in vitro study

**Authors:** Alissa Behn, Saskia Brendle, Marianne Ehrnsperger, Magdalena Zborilova, Thomas M. Grupp, Joachim Grifka, Nicole Schäfer, Susanne Grässel

PMC · DOI: 10.3389/fcell.2025.1534281 · 2025-02-27

## TL;DR

This preclinical study explores how nanofat, a fat graft, may help treat osteoarthritis by boosting cell activity and reducing pain-related factors.

## Contribution

The study reveals novel molecular insights into nanofat's effects on osteoarthritis-affected cells and compares filtration systems for nanofat preparation.

## Key findings

- Nanofat enhances chondrocyte proliferation and migration while reducing pain-related factors like β-NGF and MCP-1.
- Filtered and unfiltered nanofat show similar cellular effects, with no significant differences between filtration systems.
- Nanofat increases anti-inflammatory TGF-β1+3 and complement components while decreasing pro-inflammatory cytokines.

## Abstract

Orthobiologics, such as autologous nanofat, are emerging as a potential treatment option for osteoarthritis (OA), a common degenerative joint causing pain and disability in the elderly. Nanofat, a minimally processed human fat graft rich in stromal vascular fraction (SVF) secretory factors, has shown promise in relieving pain. This study aimed to elucidate the molecular mechanisms underlying nanofat treatment of OA-affected cells and compare two filtration systems used for nanofat preparation.

Chondrocytes and synoviocytes were isolated from articular cartilage and synovium of 22 OA-patients. Lipoaspirates from 13 OA-patients were emulsified using the Adinizer® or Lipocube™ Nano filter systems to generate nanofat. The fluid phase of SVF from both filtered and unfiltered lipoaspirates was applied to OA-affected cells. Luminex multiplex ELISA were performed with lipoaspirates and cell supernatants alongside functional assays evaluating cell migration, proliferation, metabolic activity, and senescence.

A total of 62 cytokines, chemokines, growth factors, neuropeptides, matrix-degrading enzymes, and complement components were identified in lipoaspirates. Among these, significant concentration differences were observed for TIMP-2, TGF-ß3, and complement component C3 between the filtered and unfiltered samples. Nanofat enhanced chondrocyte proliferation and migration, as well as synoviocyte migration and metabolic activity, while reducing chondrocyte metabolic activity. Pain-related factors like β-NGF, MCP-1, Substance P, VEGF, and αCGRP were reduced, while anti-inflammatory TGF-β1+3 increased and pro-inflammatory cytokines (IL-5, IL-7, IL-15, and IFN-γ) decreased. Nanofat also elevated secretion of complement components and TIMPs in both cell types. Notably, our results revealed no significant differences in cellular effects between sSVF filtered using the Adinizer® and Lipocube™ Nano systems, as well as compared to unfiltered sSVF.

Here, we provide first insights into how autologous nanofat therapy may ameliorate OA by enhancing chondrocyte proliferation and synoviocyte migration while modulating inflammatory and pain-related factors. However, further research is needed to determine its effects on cartilage regeneration.

## Linked entities

- **Proteins:** TIMP2 (TIMP metallopeptidase inhibitor 2), C3 (complement C3), CCL2 (C-C motif chemokine ligand 2), VEGFA (vascular endothelial growth factor A), TGFB1 (transforming growth factor beta 1), IL5 (interleukin 5), IL7 (interleukin 7), IL15 (interleukin 15), IFNG (interferon gamma)
- **Diseases:** osteoarthritis (MONDO:0005178)

## Full-text entities

- **Genes:** IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, TIMP2 (TIMP metallopeptidase inhibitor 2) [NCBI Gene 7077] {aka CSC-21K, DDC8}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}
- **Diseases:** inflammatory (MESH:D007249), Pain (MESH:D010146), OA (MESH:D010003), degenerative joint (MESH:D019636)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11903472/full.md

---
Source: https://tomesphere.com/paper/PMC11903472